Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis

Trial Profile

Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 14 Nov 2019 This trial has been completed in France, according to European Clinical Trials Database.
    • 08 Nov 2019 This trial has been completed in Germany, according to European Clinical Trials Database.
    • 15 Jun 2019 Results ( Data cut off: 1 Dec 2017 (Polyarticular Juvenile Idiopathic Arthritis ), and 28 Feb 2018 ( Systemic Juvenile Idiopathic Arthritis ) ) evaluating the long-term safety and efficacy of subcutaneous Tocilizumab in patients with Systemic and Polyarticular Juvenile Idiopathic Arthritis are presented at the 20th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top